As AI continues to make a profound impact on the medical imaging industry, the FDA is hosting a two-day public workshop to discuss the benefits and risks of this powerful technology.
“Evolving Role of Artificial Intelligence in Radiological Imaging,” scheduled for Feb. 25 and 26, will also included conversations based on best practices for validating AI-powered software and medical devise. The event is to be held in Bethesda, Maryland, at the National Institutes of Health’s main campus, and webcasts will also be available.
“AI, including machine learning technologies, has the potential to transform healthcare by deriving new and important insights from the vast amount of data generated during the delivery of healthcare every day,” according to the agency’s description of the event. “Radiological applications of AI-based technologies are numerous and expanding.”
The Medical Imaging and Technology Alliance (MITA) is one of numerous stakeholders invited to participate in the public workshop, with numerous representatives expected to attend.
“The potential for AI in medical imaging is enormous, and the FDA will play an important role in navigating how physicians and patients will ultimately benefit,” Dennis Durmis, chair of the MITA Board of Directors and a senior vice president at Bayer, said in a statement. “It is timely that the agency encourages innovation by supporting regulatory frameworks that are predictable, transparent and fair to all interested parties.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.